Background: Due to the lack of sensitive diagnostic biomarkers for osteoporosis (OP), there is an urgent need to identify and uncover biomarkers associated with the disease in order to facilitate early clinical diagnosis and effective intervention strategies. Methods: GEO2R was employed to conduct a screening of differentially expressed genes (DEGs) within the transcriptome sequencing data obtained from blood samples of OP patients within the GSE163849 dataset. Subsequently, we conducted expression confirmation of the identified DEGs using an additional dataset, GSE35959. To further explore Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, MicroRNA (miRNA) interactions, and drug predictions, we employed the DAVID, miRTarBase, and DrugBank databases. For validation purposes, clinical OP samples paired with normal controls were collected from the Pakistani population. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was employed to assess the expression levels of DEGs and miRNA, while targeted bisulfite sequencing (bisulfite-seq) analysis was used to investigate methylation patterns. DNA and RNA from clinical OP and normal control samples were extracted using appropriate methods. Results: Out of total identified 269 DEGs, EGFR (epidermal growth factor receptor), HMOX1 (heme oxygenase-1), PGR (progesterone receptor), CXCL10 (C-X-C motif chemokine ligand 10), CCL5 (C-C motif chemokine ligand 5), and IL12B (interleukin 12B) were prioritized as top DEGs in OP patients. Expression validation of these genes on additional Gene Expression Omnibus (GEO) dataset and Pakistani OP patients revealed consistent significant up-regulation of these genes in OP patients. Receiver operating characteristic (ROC) analysis demonstrated that these DEGs displayed considerable diagnostic accuracy for detecting OP. Targeted bisulfite-seq analysis further revealed that EGFR, HMOX1, PGR, CXCL10, CCL5, and IL12B were hypomethylated in OP patients. Moreover, has-miR-27a-5p, a common expression regulator of the EGFR, HMOX1, PGR, CXCL10, CCL5, and IL12B was also significantly down-regulated in OP patients. Conclusion: The DEGs that have been identified hold significant potential for the future development of diagnostic and treatment approaches for OP in preclinical and clinical applications.
展开▼
机译:背景: 由于缺乏敏感的骨质疏松症 (OP) 诊断生物标志物,迫切需要识别和发现与该疾病相关的生物标志物,以促进早期临床诊断和有效的干预策略。方法: 采用 GEO2R 对从 GSE163849 数据集内 OP 患者血液样本获得的转录组测序数据中的差异表达基因 (DEGs) 进行筛选。随后,我们使用另一个数据集 GSE35959 对鉴定的 DEGs 进行了表达确认。为了进一步探索基因本体论 (GO)、京都基因和基因组百科全书 (KEGG) 富集、MicroRNA (miRNA) 相互作用和药物预测,我们使用了 DAVID、miRTarBase 和 DrugBank 数据库。出于验证目的,从巴基斯坦人群中收集了与正常对照配对的临床 OP 样本。采用逆转录定量聚合酶链反应 (RT-qPCR) 评估 DEGs 和 miRNA 的表达水平,同时采用靶向亚硫酸氢盐测序 (bisulfite-seq) 分析研究甲基化模式。使用适当的方法提取临床 OP 和正常对照样品的 DNA 和 RNA。结果: 在总共确定的 269 例 DEGs 中,EGFR (表皮生长因子受体)、HMOX1 (血红素加氧酶-1)、PGR (孕激素受体)、CXCL10 (C-X-C 基序趋化因子配体 10)、CCL5 (C-C 基序趋化因子配体 5) 和 IL12B (白细胞介素 12B) 被优先考虑为 OP 患者的顶级 DEGs。在其他基因表达综合 (GEO) 数据集和巴基斯坦 OP 患者上对这些基因的表达验证显示,这些基因在 OP 患者中始终显着上调。受试者工作特征 (ROC) 分析表明,这些 DEGs 在检测 OP 方面显示出相当大的诊断准确性。靶向亚硫酸氢盐测序分析进一步揭示 OP 患者的 EGFR 、 HMOX1 、 PGR 、 CXCL10 、 CCL5 和 IL12B 低甲基化。此外,EGFR 、 HMOX1 、 PGR 、 CXCL10 、 CCL5 和 IL12B 的常见表达调节因子 hsa-miR-27a-5p 在 OP 患者中也显著下调。结论: 已确定的 DEGs 对临床前和临床应用中 OP 诊断和治疗方法的未来发展具有重要潜力。
展开▼